StoneX Group’s Iovance Biotherapeutics IOVA Stock Holding History

StoneX Group’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14,999	Closed	-$122K	–	406
2023 Q4	$122K	Buy	+14,999	New	+$78.5K	0.07%	295

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

StoneX Group's IOVA Position: Q1 2024 in Review

StoneX Group sold out of Iovance Biotherapeutics (IOVA) in Q1 2024, closing a stake of 14,999 shares — an estimated $122K sold.

StoneX Group first reported a position in IOVA in Q4 2023 and held it in 1 quarter. The position peaked at $122K in Q4 2023. 273 funds tracked by Wall St. Rank hold IOVA as of Q1 2024.

StoneX Group reported no remaining Iovance Biotherapeutics position as of Q1 2024 after selling out during the quarter.
StoneX Group sold 14,999 Iovance Biotherapeutics shares in Q1 2024, an estimated $122K.
StoneX Group first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 1 quarter.
StoneX Group's Iovance Biotherapeutics position peaked at $122K in Q4 2023.
273 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2024.

Based on StoneX Group's 13F filing for Q1 2024, filed 1 May 2024.